CP 42,096 explained

CP 42,096 is an analgesic drug which acts as a cannabinoid agonist. It was developed by Pfizer in the 1980s as part of the research that led to the development of levonantradol,^{[1] [2] [3]} and is more potent than THC but less potent than newer compounds such as CP 55,244.^{[4] [5]}

See also

• A-41988
• CP 47,497
• CP 55,940
• Canbisol
• Hexahydrocannabinol

Notes and References

1. Howlett AC, Johnson MR, Melvin LS, Milne GM . Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model . Molecular Pharmacology . 33 . 3 . 297–302 . March 1988 . 3352594 .
2. Prescott WR, Martin BR . The evaluation of synthetic cannabimimetic congeners for discriminative stimulus and cataleptogenic effects in rats . NIDA Research Monograph . 105 . 421 . 1990 . 1652087 . 7457082 .
3. Book: Koe BK . 1999 . Levonantradol . Nahas GG, Sutin KM, Harvey D, Agurell S, Pace N, Cancro R . Marihuana and Medicine. . 553–560 . Humana Press . Totowa, NJ . 10.1007/978-1-59259-710-9_53 . 978-1-4757-5717-0 .
4. Koe BK, Milne GM, Weissman A, Johnson MR, Melvin LS . Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics . European Journal of Pharmacology . 109 . 2 . 201–12 . February 1985 . 2986995 . 10.1016/0014-2999(85)90421-2 .
5. Web site: Hexahydrocannabinol (HHC) and related substances. . European Monitoring Centre for Drugs and Drug Addiction . 2023 .